Targeted Polyethylene Glycol-Linker-Drug Conjugate System
Legal Citation
Summary of the Inventive Concept
A next-generation polyethylene glycol-linker-drug conjugate system, enabling targeted delivery of various drug residues to specific cells or tissues through functional group modification of the polyethylene glycol residue.
Background and Problem Solved
The original patent disclosed a polyethylene glycol-linker-drug conjugate with limited delivery specificity. This new inventive concept addresses the need for targeted delivery of drugs to specific cells or tissues, thereby minimizing side effects and enhancing efficacy.
Detailed Description of the Inventive Concept
The polyethylene glycol-linker-drug conjugate system comprises a polyethylene glycol residue, a linking group, and a drug residue. The polyethylene glycol residue is modified to include at least one functional group for targeted delivery to specific cells or tissues. The linking group is selected from one or a combination of several of —(CH2)a—, —(CH2)aCO—, —(CH2)aOCO—, —(CH2)aNHCO—, —NH(CH2)aCO—, or —NH(CH2)aOCO—. The drug residue can be a polypeptide drug, a protein drug, a small molecule drug, a bi-specific antibody, a gene editing tool, or a combination therapy of at least two different drugs.
Novelty and Inventive Step
The new inventive concept introduces the modification of the polyethylene glycol residue with at least one functional group for targeted delivery, which is not disclosed in the original patent. This modification enables targeted delivery of various drug residues to specific cells or tissues, thereby providing a significant improvement over the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept include using different linking groups, modifying the polyethylene glycol residue with different functional groups, or using different drug residues. Variations of the inventive concept could include using different polymer backbones, modifying the drug residue for targeted delivery, or incorporating additional components for enhanced efficacy.
Potential Commercial Applications and Market
The targeted polyethylene glycol-linker-drug conjugate system has potential commercial applications in the treatment of various diseases, including cancer, genetic disorders, and inflammatory diseases. The market for targeted drug delivery systems is expected to grow significantly in the coming years, driven by the need for more effective and efficient treatments.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/60 |
| A | A61 | A61K31/704 |
| A | A61 | A61P35/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical drug delivery technologies, specifically polymer-drug conjugate systems with a focus on polyethylene glycol (PEG) linker technologies for targeted drug delivery in oncology and therapeutic applications
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical chemistry, polymer science, or biomedical engineering, having expertise in drug conjugation techniques, polymer modification, and targeted drug delivery strategies
Obviousness Rationale
A person having ordinary skill in the art would recognize that modifying the PEG-linker-drug conjugate with targeted functional groups represents a predictable extension of the source patent's core technology. The fundamental structural elements remain consistent, with the primary innovation being the strategic addition of targeting mechanisms to enhance drug delivery specificity. Such modifications align with established pharmaceutical engineering practices of improving drug targeting and efficacy through rational molecular design.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,635 |
|---|---|
| Title | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate |
| Assignee(s) | JenKem Technology Co., Ltd. (Tianjin) |